Home › Alpha-1 Antitrypsin Deficiency › New York
Alpha-1 Antitrypsin Deficiency clinical trials in New York
4 studies for Alpha-1 Antitrypsin Deficiency are looking for participants at sites in New York.
Cities in New York
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
- NYU Langone Medical Center, New York
- Columbia University Irving Medical Center, New York
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 12, 2026 · NCT06165341Gene Therapy for Alpha 1- Antitrypsin Deficiency
- WCMC Department of Genetic Medicine, New York
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Oct 16, 2026 · NCT06996756Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated May 13, 2026 · NCT05677971PiMZ Longitudinal Cohort (PiMZ Logic)
- Columbia University Irving Medical Center, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 16, 2026 · NCT06505603From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.